Skip to main content

Table 1 Baseline characteristics

From: Effects of linagliptin on endothelial function and postprandial lipids in coronary artery disease patients with early diabetes: a randomized, placebo-controlled, double-blind trial

 

Linagliptin

Control

p-valuea

Baseline

3 months

Δ

Baseline

3 months

Δ

Blood pressure systolic (mmHg)

134 ± 17

142 ± 14

8 ± 18

128 ± 18

132 ± 18

4 ± 18

0.103

Blood pressure diastolic (mmHg)

79 ± 14

81 ± 12

1 ± 14

78 ± 10

78 ± 12

0 ± 14

0.599

Low density lipoprotein (mg/dl)

66 ± 31

80 ± 34

13 ± 43

76 ± 43

78 ± 43

4 ± 23

0.408

Triglycerides (mg/dl), median (range)

145 (54 to 480)

132 (68 to 451)

− 16 (− 108 to 197)

122 (63 to 255)

146 (62 to 651)

14 (− 16 to 396)

0.173

HbA1c (mmol/mol), median (range)

50.5 (43 to 69)

49 (38 to 88)

− 2 (− 8 to 27)

51 (39 to 78)

48 (39 to 71)

0.5 (− 28 to 18)

0.029

Fasting blood glucose (mg/dl)

136 ± 41

130 ± 39

− 4 ± 18

123 ± 26

125 ± 36

4 ± 37

0.670

Aspartate-aminotransferase (U/L)

33.5 ± 14

34.9 ± 20.6

0.9 ± 21.9

27.6 ± 8.3

31.8 ± 12.9

4.7 ± 14.1

0.869

Alanine-aminotransferase (U/L)

40.4 ± 25

37.7 ± 21.7

− 3.6 ± 21.4

29 ± 12.7

29.2 ± 11.9

1.0 ± 7.4

0.905

Creatinine (mg/dL)

1.0 ± 0.3

1.0 ± 0.3

0.0 ± 0.1

1.0 ± 0.2

1.0 ± 0.2

0.0 ± 0.1

0.327

eGFR (ml/min)

76.7 ± 16.1

73.2 ± 17.6

− 2.5 ± 11.4

80.8 ± 18.0

81.3 ± 17.5

0.5 ± 8.6

0.245

NT-proBNP (pg/ml)

419 ± 528

486 ± 519

65 ± 377

228 ± 452

232 ± 589

4 ± 192

0.543

c-Reactive protein (mg/L)

3.8 ± 4.2

2.4 ± 3.0

− 1.5 ± 2.5

7.6 ± 20.4

3.3 ± 4.5

− 4.6 ± 21.2

0.548

  1. eGFR estimated glomerular filtration rate, NT-proBNP N-terminal pro b-type natriuretic peptide
  2. ap values based on analysis of covariance except for triglycerides and HbA1c (Mann–Whitney-U-test for differences). Δ reflects difference between 3 months and baseline. Data are mean ± SD unless otherwise stated